Skip to main content
  • Original article
  • Open access
  • Published:

Noninvasive assessment of hepatic fibrosis regression in hepatitis C virus-infected patients treated with sofosbuvir-based therapy

Abstract

Background

Accurate evaluation of the degree of liver fibrosis in patients with chronic liver diseases is crucial to make therapeutic decisions and to determine the prognosis of liver disease and also the protocol of further follow-up. Multiple noninvasive methods have been used successfully in the prediction of fibrosis; however, early changes in noninvasive parameters of hepatic fibrosis after effective antiviral therapy are still not well unknown. The aim of the paper was to evaluate early changes in the hepatic fibrosis-related parameters in patients with chronic hepatitis C virus (HCV) infection using shear wave elastography (pSWE) and serum parameters [aspartate aminotransferase-platelet ratio index (APRI) and fibrosis-4 score (FIB4)] before and 24 weeks after sofosbuvir-based antiviral therapy.

Materials and methods

This is a prospective cohort study that included 109 Egyptian patients with chronic hepatitis C. pSWE values were recorded as well as APRI and FIB4 scores were calculated at baseline and at 12 and 24 weeks after treatment.

Results

A total of 109 HCV-infected patients were included, with mean age of 45.76±13.91 years. Overall, 25 (22.90%) patients had cirrhosis and were treated with sofosbuvir 400 mg/day, daclatasvir 60mg/day, and weight-based ribavirin. Moreover, 84 (77.10%) were treated with sofosbuvir 400 mg/day and daclatasvir 60mg/day. The overall sustained virological response-12 rate was 100%. There were significant improvements in APRI score (from 0.64±0.66 at baseline to 0.26±0.22 at 24 weeks after treatment) and FIB4 score (from 1.77±1.77 at baseline to 1.11±1.04 at 24 weeks after treatment), with P value of 0.0001 in both. In addition, there was a significant reduction in liver stiffness measurements by pSWE 24 weeks after treatment (from 1.72±0.55 m/s at baseline to 1.48±0.44 m/s at 24 weeks after treatment, with P=0.003).

Conclusion

Sofosbuvir-based treatment regimens for chronic HCV infection result in significant improvement of the fibrosis scores (FIB4 and APRI) 24 weeks after treatment. Moreover, there was a significant reduction in the liver stiffness measurements by pSWE.

References

  1. World Health Organization. Hepatitis C Fact sheet 2016, WHO.

  2. Van der Meer AJ. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308:2584–2593.

    Article  Google Scholar 

  3. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825–832.

    CAS  PubMed  Google Scholar 

  4. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36:S47–S56.

    PubMed  Google Scholar 

  5. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med 2013; 159:372.

    Article  Google Scholar 

  6. Yosry A, Fouad R, Alem SA, Elsharkawy A, El-Sayed M, Asem N, et al. FibroScan, APRI, FIB4, and GUCI: role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. Arab J Gastroenterol 2016; 17:78–83.

    Article  Google Scholar 

  7. D’Ambrosio R, Aghemo A, Fraquelli M, Rumi MG, Donato MF, Paradis V, et al. The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013; 59:251–256.

    Article  Google Scholar 

  8. Shiina T, Nightingale KR, Palmeri ML, Hall TJ, Bamber JC, Barr RG, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: part 1: basic principles and terminology. Ultrasound Med Biol 2015; 41:1126–1147.

    Article  Google Scholar 

  9. Bota S, Herkner H, Sporea I, Salzl P, Sirli R, Neghina AM, et al. Meta-analysis: ARFI elastography versus transient elastography for the evaluation of liver fibrosis. Liver Int 2013; 33(8):1138–1147.

    Article  Google Scholar 

  10. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518–526.

    Article  Google Scholar 

  11. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV co-infection. Hepatology 2006; 43:1317–1325.

    Article  CAS  Google Scholar 

  12. European Association for Study of Liver (EASL). Recommendations on treatment of hepatitis C 2015. Journal of Hepatology 2015; 63:199.

    Article  Google Scholar 

  13. Lupsor M, Badea R, Stefanescu H, Sparchez Z, Branda H, Serban A, et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis 2009; 18:303–310.

    PubMed  Google Scholar 

  14. Welzel TM, Petersen J, Herzer K, Ferenci P, Gschwantler M, Wedemeyer H, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 2016; 65:1861–1870.

    Article  CAS  Google Scholar 

  15. Ahmed OA, Safwat E, Khalifa MO, Elshafie AI, Fouad MHA, Salama MM, et al. Sofosbuvir plus daclatasvir in treatment of chronic hepatitis C genotype 4 infection in a cohort of Egyptian patients: an experiment the size of Egyptian village. Int J Hepatol 2018; 9:162–174.

    Google Scholar 

  16. Bernuth S, Yagmur E, Schuppan D, Sprinzl MF, Zimmermann A, Schad A, et al. Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir. Dig Liver Dis 2016; 48:291–297.

    Article  CAS  Google Scholar 

  17. Elsharkawy A, Eletreby R, Fouad R, Soliman Z, Abdallah M, Negm M, et al. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Rev Gastroenterol Hepatol 2017; 11:773–778.

    Article  CAS  Google Scholar 

  18. Wu LS, Jimmerson LC, MacBrayne CE, Kiser JJ, D’Argenio DZ. Modeling ribavirin-induced anemia in patients with chronic hepatitis C virus. CPT Pharmacometrics Syst Pharmacol 2016; 5:65–73.

    Article  CAS  Google Scholar 

  19. Shousha HI, Mehassab MK, Mehrez MI, Afifi SA, Elsharkawy M, Hamed M, et al. Non-invasive fibrosis scores and liver stiffness changes in chronic hepatitis C after sofosbuvir-based treatment. Int J Hepatol Gastroenterol 2017; 3:085–090.

    Google Scholar 

  20. Knop V, Hoppe D, Welzel T, Vermehren J, Herrmann E, Vermehren A, et al. Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 2016; 23:994–1002.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Heba Aly.

Additional information

This is an open access journal, and articl es are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Khattib, A., El-Nakeeb, A., Musa, N.I. et al. Noninvasive assessment of hepatic fibrosis regression in hepatitis C virus-infected patients treated with sofosbuvir-based therapy. Egypt J Intern Med 31, 556–562 (2019). https://doi.org/10.4103/ejim.ejim_92_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_92_19

Keywords